COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 7 FDA records to the applicant name Siemens Medical Solutions Diagnostics Limited. It includes 1 original PMA approval. 1 entry is a PMA supplement. 5 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from May 11, 2007 to Sep 22, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MTG appears in 7 of the 7 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P060005, with 7 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: Glyn Rhonwy Llanberis, Caernarfon, Gwynedd Ll55, 4EL. Recorded on P060005/S027, decision dated Sep 22, 2026.
Device categories in this collection
Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions.
Changes described in PMA records
The FDA recorded a 30-Day Notice decision, OK30, dated 2026-09-22 for P060005/S027, a supplement to the IMMULITE Systems Free PSA application held by Siemens Medical Solutions Diagnostics Limited. The supplement type is a 30-Day Notice and the recorded reason is a process change affecting a manufacturer, sterilizer, packager or supplier. The stated scope is to move manufacturing of a critical component within the same facility.
The underlying device category is a free prostate specific antigen (noncomplexed) test intended to distinguish prostate cancer from benign conditions, classified under Immunology with product code MTG. This record covers only the manufacturing-location change described; it is not a new approval of the whole system, and the source does not identify the component, the facility, or any performance data. Whether the change affects analytical performance or labeling remains unknown from this record.
FDA approval-order wording
to move manufacturing of a critical component within the same facility
Sep 22, 2026 · 30-Day NoticeFDA’s recorded scope: Approval of the change to the bead drying process used in the manufacture of bead components for the IMMULITE 2000 AFP, Free PSA, and PSA assays.
Aug 20, 2026 · 30-Day NoticeFDA’s recorded scope: Approval of the change to in-process manufacturing quality testing for the IMMULITE 2000 XPi analyzers and IMMULITE 2000 / IMMULITE 2000 XPi spare probe assemblies.
Jul 27, 2026 · 30-Day NoticeFDA’s recorded scope: approval of the instrument manufacturing site change for the IMMULITE 2000XPi analyzer to the Siemens Healthcare Diagnostics instrument manufacturing facility located in Llanberis, Wales
Apr 21, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: Approval for the move of critical raw material operations of an internal supplier in-house to an internal company site.
Oct 30, 2025 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.